10 search results for: feno

<b>FeNO</b>: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

5 min

Pulmonology

Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma.

<b>FeNO</b> as a Biomarker for Type 2 Asthma

expert video

FeNO as a Biomarker for Type 2 Asthma

16 min

Pulmonology

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation and its role in the disease burden of asthma.

How Can <b>FeNO</b> Support the Management of Pediatric Asthma?

expert video

How Can FeNO Support the Management of Pediatric Asthma?

2 min

Pulmonology

Dr. Michael Blaiss discusses the importance of measuring FeNO in pediatric asthma patients.

What is the Role of <b>FeNO</b> as an Asthma Biomarker?

expert video

What is the Role of FeNO as an Asthma Biomarker?

2 min

Pulmonology

Prof. Klaus Rabe and Dr. Michael Wechsler explore the utility of FeNO as a biomarker in asthma.

expert video

How Can FeNO Measurement Improve Severe Asthma Management?

7 min

Pulmonology

Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.

Infographic

Adult Lung Function Static Infographic

5 min

Pulmonology

Review this infographic on lung function

interactivity

Type 2 Inflammation Digital Assessment Tool

4 min

Pulmonology

Learn how to assess patients for the presence of uncontrolled asthma driven by underlying type 2 inflammation.

Podcast

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

22 min

Pulmonology

Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.

expert video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

42 min

Pulmonology

Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region